BidaskClub downgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a sell rating in a research report released on Thursday.
A number of other research firms have also weighed in on ANIP. Canaccord Genuity set a $77.00 target price on shares of ANI Pharmaceuticals and gave the stock a buy rating in a research note on Friday, December 29th. ValuEngine raised shares of ANI Pharmaceuticals from a hold rating to a buy rating in a research note on Saturday, November 4th. TheStreet raised shares of ANI Pharmaceuticals from a c+ rating to a b rating in a research note on Thursday, November 16th. Finally, Zacks Investment Research lowered shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $71.00.
Shares of ANI Pharmaceuticals (NASDAQ:ANIP) opened at $57.64 on Thursday. The company has a quick ratio of 2.39, a current ratio of 3.45 and a debt-to-equity ratio of 0.83. ANI Pharmaceuticals has a twelve month low of $42.23 and a twelve month high of $74.70. The stock has a market capitalization of $675.17, a PE ratio of 17.30 and a beta of 2.79.
Several hedge funds have recently added to or reduced their stakes in the company. MetLife Investment Advisors LLC purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at approximately $254,000. Jane Street Group LLC purchased a new stake in ANI Pharmaceuticals in the fourth quarter valued at approximately $411,000. Millennium Management LLC purchased a new stake in ANI Pharmaceuticals in the fourth quarter valued at approximately $210,000. Cornerstone Capital Management Holdings LLC. purchased a new stake in ANI Pharmaceuticals in the fourth quarter valued at approximately $895,000. Finally, Nexthera Capital LP purchased a new stake in ANI Pharmaceuticals in the fourth quarter valued at approximately $2,701,000. 53.92% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “ANI Pharmaceuticals (ANIP) Cut to Sell at BidaskClub” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/23/ani-pharmaceuticals-anip-cut-to-sell-at-bidaskclub.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.